title: [Guidelines for the management of Crohn's disease].
abstract: Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with uncertain etiopathogenesis. CD can involve any site of gastrointestinal tract from the mouth to anus and is associated with serious complications such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies are currently applied for diverse clinical situations of CD. However, a lot of decisions on the management of CD are made depending on the personal experiences and choices of physicians. To suggest preferable approaches to diverse problems of CD and to minimize the variations according to physicians, guidelines for the management of CD are needed. Therefore, IBD Study Group of the Korean Association for the Study of the Intestinal Diseases has set out to develop the guidelines for the management of CD in Korea. These guidelines were developed using the adaptation methods and encompass the treatment of inflammatory disease, stricturing disease, and penetrating disease. The guidelines also cover the indication of surgery, prevention of recurrence after surgery, and CD in pregnancy and lactation. These are the first Korean guidelines for the management of CD and the update with further scientific data and evidences is needed.
authors.affiliation: Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Byong Duk
authors.initials: BD
authors.lastname: Ye
authors.forename: Suk-Kyun
authors.initials: SK
authors.lastname: Yang
authors.forename: Sung Jae
authors.initials: SJ
authors.lastname: Shin
authors.forename: Kang Moon
authors.initials: KM
authors.lastname: Lee
authors.forename: Byung Ik
authors.initials: BI
authors.lastname: Jang
authors.forename: Jae Hee
authors.initials: JH
authors.lastname: Cheon
authors.forename: Chang Hwan
authors.initials: CH
authors.lastname: Choi
authors.forename: Young-Ho
authors.initials: YH
authors.lastname: Kim
authors.forename: Heeyoung
authors.initials: H
authors.lastname: Lee
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D016208:Databases, Factual; D005260:Female; D005402:Fistula / Q000628:therapy; D006801:Humans; D000069285:Infliximab; D007416:Intestinal Perforation / Q000601:surgery / Q000628:therapy; D008297:Male; D015122:Mercaptopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019804:Mesalamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011247:Pregnancy; D012008:Recurrence; D012307:Risk Factors; D012720:Severity of Illness Index; D012460:Sulfasalazine / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; C488629:azathiopurine; D012460:Sulfasalazine; D019804:Mesalamine; D019819:Budesonide; D011239:Prednisolone; D000069285:Infliximab; D015122:Mercaptopurine; D008727:Methotrexate